2015
Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial.
Jakubovski E, Carlson JP, Bloch MH. Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial. The Journal Of Clinical Psychiatry 2015, 76: 1535-45. PMID: 26581028, DOI: 10.4088/jcp.14m09320.Peer-Reviewed Original ResearchConceptsIntervention Effectiveness (CATIE) trialTreatment outcomesClinical Antipsychotic TrialsBaseline characteristicsTreatment continuationCATIE trialAntipsychotic pharmacotherapyPrognostic subgroupsEffectiveness trialAntipsychotic TrialsLogistic regressionROC analysisMonths of treatmentImportant treatment outcomesDSM-IV diagnosisPatients' social isolationNegative Syndrome ScaleSocial isolationPoor outcomeZiprasidone treatmentAntipsychotic treatmentComorbid depressionSide effectsPsychosocial factorsSyndrome ScalePredictors of anxiety recurrence in the Coordinated Anxiety Learning and Management (CALM) trial
Taylor JH, Jakubovski E, Bloch MH. Predictors of anxiety recurrence in the Coordinated Anxiety Learning and Management (CALM) trial. Journal Of Psychiatric Research 2015, 65: 154-165. PMID: 25896121, PMCID: PMC4492801, DOI: 10.1016/j.jpsychires.2015.03.020.Peer-Reviewed Original ResearchConceptsCoordinated Anxiety LearningAnxiety recurrenceAnxiety LearningAnxiety Sensitivity Index scoreUsual careCognitive behavioral therapyRelapse prevention programAnxiety remissionBehavioral therapyAnxiety disordersMultivariable logistic regression modelResidual anxietyCollaborative care interventionPrimary care clinicsPrimary care settingRisk of recurrenceComorbid depressionManagement trialsReceiver Operating CharacteristicLogistic regression modelsMonth 6Care clinicsPrevention programsPrognostic subgroupsCare interventions
2014
Prognostic subgroups for remission and response in the Coordinated Anxiety Learning and Management (CALM) trial.
Kelly JM, Jakubovski E, Bloch MH. Prognostic subgroups for remission and response in the Coordinated Anxiety Learning and Management (CALM) trial. The Journal Of Clinical Psychiatry 2014, 76: 267-78. PMID: 25562579, PMCID: PMC4930076, DOI: 10.4088/jcp.13m08922.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenergic Uptake InhibitorsAdultAgedAnti-Anxiety AgentsAnxiety DisordersBenzodiazepinesCognitive Behavioral TherapyCombined Modality TherapyDepressive Disorder, MajorFemaleHumansMaleMiddle AgedOutcome Assessment, Health CarePanic DisorderPhobic DisordersPrognosisRemission InductionSelective Serotonin Reuptake InhibitorsSeverity of Illness IndexSex FactorsSocial ClassSocial SupportStress Disorders, Post-TraumaticYoung AdultConceptsLow socioeconomic statusCoordinated Anxiety LearningUsual careGeneralized anxiety disorderPosttraumatic stress disorderAnxiety disordersBaseline characteristicsPatient characteristicsPrognostic subgroupsAnxiety LearningSocioeconomic statusBaseline patient characteristicsCollaborative care interventionPrimary care settingPoor treatment outcomesCommunity treatment centersDSM-IV criteriaManagement trialsCognitive behavioral therapyLimited social supportExploratory moderator analysesMost patientsRemission criteriaComorbid depressionPrognostic outcomes
2013
Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive–compulsive disorder and a history of major depressive disorder
Niciu MJ, Grunschel B, Corlett PR, Pittenger C, Bloch MH. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive–compulsive disorder and a history of major depressive disorder. Journal Of Psychopharmacology 2013, 27: 651-654. PMID: 23676198, DOI: 10.1177/0269881113486718.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderAntidepressant effectsPsychiatric comorbidityComorbid depressionNon-competitive N-methyl-D-aspartate (NMDA) receptor antagonistN-methyl-D-aspartate receptor antagonistTreatment-refractory obsessive-compulsive disorderAcute antidepressant effectsTreatment-resistant unipolarOpen-label trialSevere respiratory depressionAdverse neuropsychiatric effectsComorbid psychiatric disordersMinimal depressive symptomsOff-label useMajor depressive disorderStart of infusionRespiratory depressionIntravenous ketamineNeuropsychiatric effectsKetamine infusionBipolar depressionReceptor antagonistDepressive disorderSedative effectsAge and Gender Correlates of Pulling in Pediatric Trichotillomania
Panza KE, Pittenger C, Bloch MH. Age and Gender Correlates of Pulling in Pediatric Trichotillomania. Journal Of The American Academy Of Child & Adolescent Psychiatry 2013, 52: 241-249. PMID: 23452681, PMCID: PMC3745006, DOI: 10.1016/j.jaac.2012.12.019.Peer-Reviewed Original ResearchConceptsFrequent urgesCommon comorbid conditionsPediatric trichotillomaniaProspective longitudinal studyType of treatmentCross-sectional findingsClinical characteristicsComorbid conditionsStructured rating scaleTreatment trialsComorbid depressionRating ScaleAnxiety disordersOlder childrenTrichotillomaniaDecreased abilityLongitudinal studyMale participantsAgeChildrenGreater distressFemale participantsLower ratesSymptomsGender correlates
2012
Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder
Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C. Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder. Biological Psychiatry 2012, 72: 964-970. PMID: 22784486, PMCID: PMC3667652, DOI: 10.1016/j.biopsych.2012.05.028.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderKetamine infusionDepression symptomsLow-dose ketamine infusionTreatment-refractory obsessive-compulsive disorderOCD symptomsPathogenesis of OCDIncomplete symptom reliefTreatment-Refractory ObsessiveOpen-label trialRapid antidepressant effectsAspartate glutamate receptorsEffects of ketaminePotent noncompetitive antagonistGlutamate abnormalitiesAntidepressant effectsAntidepressant responseSymptom reliefKetamine effectsComorbid depressionAcute effectsGlutamate receptorsDepressive symptomsNoncompetitive antagonistInfusionSystematic Review of Proinflammatory Cytokines in Obsessive-Compulsive Disorder
Gray SM, Bloch MH. Systematic Review of Proinflammatory Cytokines in Obsessive-Compulsive Disorder. Current Psychiatry Reports 2012, 14: 220-228. PMID: 22477442, PMCID: PMC3625952, DOI: 10.1007/s11920-012-0272-0.Peer-Reviewed Original ResearchConceptsIL-6 levelsStratified subgroup analysisTNF-α levelsObsessive-compulsive disorderProinflammatory cytokinesComorbid depressionMedication useIL-6Subgroup analysisCerebrospinal fluid cytokine levelsElevated TNF-α levelsPlasma IL-6 levelsLower plasma IL-6 levelsIL-1β levelsTumor necrosis factorCytokine levelsEffect of ageSerum levelsPsychotropic medicationsPlasma levelsNecrosis factorInclusion criteriaImmune functionPotential confoundingSystematic review
2011
Dimensional correlates of poor insight in obsessive–compulsive disorder
Jakubovski E, Pittenger C, Torres AR, Fontenelle LF, do Rosario MC, Ferrão YA, de Mathis MA, Miguel EC, Bloch MH. Dimensional correlates of poor insight in obsessive–compulsive disorder. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2011, 35: 1677-1681. PMID: 21640153, PMCID: PMC4048951, DOI: 10.1016/j.pnpbp.2011.05.012.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderPoor insightYale-Brown ObsessiveSymptom severityTreatment responseCompulsive ScaleAxis I DSMLevel of insightDetailed clinical assessmentCross-sectional studyTotal symptom severityStructured Clinical InterviewLarge clinical cohortOCD severityDimensional correlatesSocio-demographic questionnaireClinical variablesPharmacological trialsComorbid depressionBrazilian patientsClinical assessmentClinical cohortBrown AssessmentClinical InterviewPatients